July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Audit of anti-VEGF injections for diabetic macula edema in 21 UK hospitals
Author Affiliations & Notes
  • Peter Henry Scanlon
    Ophthalmology, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom
    Harris Manchester College, University of Oxford, Oxford, United Kingdom
  • Irene Stratton
    Ophthalmology, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom
  • Clare Bailey
    Bristol Eye Hospital, Bristol, United Kingdom
  • Haralobos Eleftheriadis
    Kings College, London, United Kingdom
  • Naren Dhingra
    Mid Yorkshire NHS Trust, Wakefield, United Kingdom
  • James S Talks
    Newcastle upon Tyne Hospital, Newcastle, United Kingdom
  • Tunde Peto
    Queen's University, Belfast, United Kingdom
  • Footnotes
    Commercial Relationships   Peter Scanlon, Bayer Ltd (F); Irene Stratton, Bayer Ltd (F); Clare Bailey, Bayer Ltd (F); Haralobos Eleftheriadis, Bayer Ltd (F); Naren Dhingra, Bayer Ltd (F); James Talks, Bayer Ltd (F); Tunde Peto, Bayer Ltd (F)
  • Footnotes
    Support  Bayer Ltd have supported this study
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3607. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter Henry Scanlon, Irene Stratton, Clare Bailey, Haralobos Eleftheriadis, Naren Dhingra, James S Talks, Tunde Peto; Audit of anti-VEGF injections for diabetic macula edema in 21 UK hospitals
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):3607. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To characterise demographic data and clinical data for patients with diabetic macula edema DME in 21 UK centres

Methods : Electronic patient records were extracted in August 2017. The first treated eyes of 1937 people with DME treated with either or both of aflibercept and ranibizumab included. Descriptive statistics for baseline characteristics were derived.

Results : Of those included 764 (39%) were women. Of those first treated before August 2016 74% had follow-up data at 12 months. Median results at first injection (25th to 75th centile) were: age 65 years (56-74), Best Measured Visual Acuity (BMVA) 6/19 (6/12 to 6/30) (Snellen), Index Multiple Deprivation scores 20 (11 to 34). Type of diabetes was recorded in 1489 (77%), of these 1273 (85.5%) had Type 2 diabetes. The median number of injections in those followed for 12 months was 7 (5 to 8). For those with BMVA at baseline and at 12 months median improvement was 6 letters (0 to 13).
There was significant heterogeneity between centres, median age at first injection ranging from 61 to 72 years, BMVA 6/12 to 6/30, the proportion with data available at 12 months 68% to 85%, median number of injections in first year 6 to 8, median improvement over 12 months 0 to 11 letters.

Conclusions : Age, baseline VA, number of injections and variable follow-up should be considered when comparing visual outcomes between centres.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.